Pfizer Pays Out On Rituximab Biosimilar
Ruxience Launched In Both US And Japan
Agreements signed between Wyeth and Trubion Pharmaceuticals more than a decade ago have led to Pfizer making royalty payments on its rituximab biosimilar, Ruxience, to Aptevo Therapeutics.
You may also be interested in...
Pfizer has received European Commission approval for the firm’s Ruxience biosimilar to Roche’s MabThera brand, including as a treatment for rheumatoid arthritis, opening the door to a three-way biosimilar fight in the European Union.
With an eye on moving to market its broad pipeline of innovative brands, Pfizer has cut development of five early-stage biosimilar assets, in a decision that will affect 150 staff. The move is not reflective of Pfizer's overall commitment to biosimilars, the US-based company maintains.
Pfizer has discontinued development of Trubion Pharmaceuticals' TRU-015, which was in Phase II development for the treatment of rheumatoid arthritis under the companies' CD20 collaboration. However, it intends to continue development of a follow-on compound, SBI-087.